CoChat

Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma

Open access
Kudo, Masatoshi · 2018 · Liver Cancer
Cited by 69

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The results of a clinical trial of lenvatinib were published in the Lancet earlier this year [1]. According to the results, the response rate was higher for lenvatinib than for any other known molecular targeted agents in hepatocellular carcinoma (HCC) patients. The response rates based on independent imaging review and investigator review according to the modified RECIST (mRECIST) assessment were extremely high at 40.6 and 24.1%, respectively. The response rate based on independent imaging review according to RECIST 1.1 was also high (18.8%) (Table ​(Table1).1). The response to locoregional treatment (e.g., transcatheter arterial chemoembolization [TACE] and ablation) is correlated with overall survival (OS). In a meta-analysis of seven studies, Vincenzi et al. [2] showed that the hazard ratio (HR) for OS was 0.39 (95% confidence interval [CI] 0.26–0.61, p < 0.0001) when comparing responders and nonresponders among 1,352 patients treated with TACE (n = 1,236), cryoablation (n = 64), and bland transarterial embolization (n = 57). This excellent HR indicated the correlation between response to locoregional therapy and OS benefit (Fig. ​(Fig.1).1). It is established evidence that OS benefit is more prominent in responders to locoregional therapy than in nonresponders evaluated by mRECIST; thus, the evidence that objective response measured by mRECIST predicts survival in patients receiving locoregional therapies is currently recommended in the EASL guidelines [3]. Regarding molecular targeted agents, most sorafenib-treated patients show stable disease, demonstrating the survival benefit of sorafenib treatment. However, the association between response to molecular targeted agents and improved survival remains unclear. This article reviews recent reports based on retrospective studies and prospective clinical trials of molecular targeted agents with an emphasis on the relationship between response to these agents and improvement of patient survival. Open in a separate window Fig. 1. Correlation between objective response and improved OS in early- or intermediate-stage HCC (from Vincenzi et al. [2]).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000492533

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

Metadata

Authors
Kudo, M.
Venue
Liver Cancer
Publisher
S. Karger AG
Published
2018
Volume
7
Issue
3
Pages
215-224
ISSN
  • 1664-5553 (ISSN-L)
  • 2235-1795
OpenAlex
W2888117448
Cited by
69
References
1
FWCI
5.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.